Statin Use Over 65 Years of Age and All-Cause Mortality Statin Use Over 65 Years of Age and All-Cause Mortality

What have we learned about the effects of long-term statin therapy among this age group? Is it beneficial?Journal of the American Geriatrics Society
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Related Links:

AbstractNo studies evaluating the association between statins and outcomes of patients with seasonal influenza have been performed since the 2007 –2008 and the 2009 pandemic H1N1 influenza seasons. All consecutive hospitalized patients between October 2017 and April 2018, diagnosed with laboratory-confirmed influenza A and B virus, were included. Patients were divided into two groups: statin and non-statin users. Outcomes were 30- and 90-da y mortality, complications (pneumonia, myocarditis, encephalitis, intensive care unit (ICU) transfer, mechanical ventilation, vasopressor support), length of hospital stay, and re...
Source: European Journal of Clinical Microbiology and Infectious Diseases - Category: Microbiology Source Type: research
A 64-year-old woman with a significant medical history sees her cardiologist for a routine follow-up after a second MI. How do you minimize her risk for future ASCVD events?American College of Cardiology &Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Clinical Case Source Type: news
Icosapent ethyl (Vascepa, Amarin) was unanimously recommended for approval as an adjunct to statin therapy. However, the exact population for whom the drug should be prescribed was not decided.News Alerts
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news
Molecules, Vol. 24, Pages 4140: Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE−/− Mice Molecules doi: 10.3390/molecules24224140 Authors: Lili Gu Yaqin Gong Cheng Zhao Yue Wang Qinghua Tian Gaoxin Lei Yalin Liang Wenfeng Zhao Shuhua Tan Statins are the most popular therapeutic drugs to lower plasma low density lipoprotein cholesterol (LDL-C) synthesis by competitively inhibiting hydroxyl-3-methyl-glutaryl-CoA (HMG-CoA) reductase and up-regulating the hepatic low density lipoprotein receptor (LDLR). However, the concomita...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Roughly six million people in Britain are thought to take statins and it is estimated that up to 30million people take the life-saving pills in the US.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
ConclusionsAlthough most high-risk patients with T2D and CV disease were on lipid-lowering therapy, only 1:3 had LDL-C 
Source: American Heart Journal - Category: Cardiology Source Type: research
Publication date: Available online 12 November 2019Source: American Heart JournalAuthor(s): Franck Boccara, Princy Kumar, Bruno Caramelli, Alexandra Calmy, J. Antonio G. López, Sarah Bray, Marcoli Cyrille, Robert S. RosensonBackgroundPeople living with human immunodeficiency virus (PLHIV) are at higher risk of atherosclerotic cardiovascular disease (ASCVD) due to traditional and HIV- or antiretroviral treatment (ART)-related risk factors. The use of high-intensity statin therapy is often limited by comorbidities and drug–drug interactions with ART. Herein, we present the design and baseline characteristics of ...
Source: American Heart Journal - Category: Cardiology Source Type: research
AbstractIntroductionPatients with atherosclerotic cardiovascular disease (ASCVD), especially those with recent (
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
The recently published ESC/EAS guidelines for the management of dyslipidaemias have lowered the low-density lipoprotein cholesterol (LDL-C) target in the very high risk patients below 55 mg/dL [1.4 mmol/L] [1]. The drug of choice for achieving this target is high-intensity statin to the highest tolerated dose. If the goal is not achieved, the addition of ezetimibe is recommended first, and then the addition of a proprotein convertase subtilisin/kexin type [9] inhibitor (PCSK9i), if LDL-C remains above target.
Source: Atherosclerosis - Category: Cardiology Authors: Tags: Correspondence Source Type: research
AbstractPurpose of the ReviewPeripheral artery disease (PAD) affects close to 200 million people worldwide. Claudication is the most common presenting symptom for patients with PAD. This review summarizes the current diagnostic and treatment options for patients with claudication. Comprehensive history and physical examination in order to differentiate between claudication secondary to vascular disease vs. neurogenic causes is paramount for initial diagnosis. Ankle-brachial index is the most commonly used test for screening and diagnostic purposes. Treatment consists of four different approaches, which are best utilized in...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
More News: Cholesterol | Geriatrics | Health | Internal Medicine | Statin Therapy